|
US11583593B2
(en)
|
2016-01-14 |
2023-02-21 |
Synthis Therapeutics, Inc. |
Antibody-ALK5 inhibitor conjugates and their uses
|
|
CN109843327B
(zh)
|
2016-07-07 |
2022-05-13 |
小利兰·斯坦福大学托管委员会 |
抗体佐剂缀合物
|
|
US10676516B2
(en)
|
2017-05-24 |
2020-06-09 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
US10174092B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
MX2020012679A
(es)
*
|
2018-05-25 |
2021-02-09 |
Silverback Therapeutics Inc |
Compuestos de amino-pirazincarboxamida, conjugados, y usos de los mismos.
|
|
CN111018857B
(zh)
*
|
2018-10-09 |
2023-06-02 |
嘉兴优博生物技术有限公司 |
靶向蛋白酶降解平台(ted)
|
|
EA202190986A1
(ru)
|
2018-11-26 |
2021-12-14 |
Фоти Севен, Инк. |
ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К c-Kit
|
|
WO2020190725A1
(en)
|
2019-03-15 |
2020-09-24 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting her2
|
|
EP3725370A1
(en)
|
2019-04-19 |
2020-10-21 |
ImmunoBrain Checkpoint, Inc. |
Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
|
|
JP7682102B2
(ja)
*
|
2019-05-10 |
2025-05-23 |
リビジェン バイオファーマ ホールディングス リミテッド |
ヒト化抗ｃｄ１３７抗体およびその使用
|
|
BR112021023345A2
(pt)
|
2019-05-20 |
2022-02-01 |
Pandion Operations Inc |
Imunotolerância com alvo em madcam
|
|
US20220267467A1
(en)
*
|
2019-07-19 |
2022-08-25 |
WuXi Biologics Ireland Limited |
Polypeptide complex for conjugation and use thereof
|
|
WO2021023117A1
(zh)
*
|
2019-08-02 |
2021-02-11 |
康方药业有限公司 |
抗ctla4-抗pd-1双特异性抗体及其用途
|
|
WO2021102332A1
(en)
*
|
2019-11-22 |
2021-05-27 |
Silverback Therapeutics, Inc. |
Tgfbetar2 inhibitor-lrrc15 antibody conjugates and uses thereof
|
|
WO2021118968A1
(en)
*
|
2019-12-12 |
2021-06-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-drug conjugates specific for cd276 and uses thereof
|
|
JP2023509760A
(ja)
*
|
2020-01-08 |
2023-03-09 |
シンシス セラピューティクス，インコーポレイテッド |
Ａｌｋ５阻害剤複合体およびその使用
|
|
TWI854088B
(zh)
*
|
2020-01-27 |
2024-09-01 |
英商梅迪繆思有限公司 |
用於治療腎臟疾病之抗αｖβ８整聯蛋白抗體
|
|
EP4107187A4
(en)
|
2020-02-21 |
2024-07-03 |
Pandion Operations, Inc. |
TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
|
|
JP7735291B2
(ja)
|
2020-02-21 |
2025-09-08 |
エーアールエス ファーマシューティカルズ、インコーポレイテッド |
ネクチン－４抗体コンジュゲートおよびその使用
|
|
AU2021246485A1
(en)
*
|
2020-04-01 |
2022-11-17 |
The Regents Of The University Of California |
Immunotheranostic agent targeting mesenchymal stem cell-derived cancer cells and mesenchymal stem cell associated disease
|
|
CN113509557A
(zh)
*
|
2020-04-09 |
2021-10-19 |
嘉兴优博生物技术有限公司 |
靶向蛋白酶降解平台(ted)
|
|
EP4149627A4
(en)
*
|
2020-05-14 |
2024-05-29 |
The General Hospital Corporation |
POLYPEPTIDE AGONISTS OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY
|
|
WO2021243136A2
(en)
*
|
2020-05-29 |
2021-12-02 |
New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery |
Methods and compositions for treating, preventing the onset and/or slowing progression of osteoarthritis
|
|
EP4157883A4
(en)
*
|
2020-06-02 |
2024-12-04 |
Children's Medical Center Corporation |
NANOBODY CONJUGATES (VHH) AND THEIR USES
|
|
JP2023532304A
(ja)
|
2020-07-01 |
2023-07-27 |
エーアールエス ファーマシューティカルズ オペレーションズ，インク． |
抗ａｓｇｒ１抗体コンジュゲートおよびその使用
|
|
KR102506295B1
(ko)
*
|
2020-08-28 |
2023-03-08 |
국립암센터 |
디그옥시제닌에 대한 인간화 항체 및 이의 용도
|
|
CN114146095A
(zh)
*
|
2020-09-07 |
2022-03-08 |
是光隽恒(北京)生物科技有限公司 |
用于组织损伤修复的组合物及其制备方法和用途
|
|
CN116615442A
(zh)
*
|
2020-09-08 |
2023-08-18 |
优特力克斯有限公司 |
程序性细胞死亡1多肽变体
|
|
EP4247434A4
(en)
*
|
2020-11-18 |
2024-10-23 |
Pandion Operations, Inc. |
THERAPEUTIC AGENTS TARGETING MADCAM AND THEIR USES
|
|
IL306129A
(en)
*
|
2021-04-07 |
2023-11-01 |
Mythic Therapeutics Inc |
Structures of antigen-binding proteins and antibodies and their uses
|
|
US20240209080A1
(en)
|
2021-04-10 |
2024-06-27 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
CA3216459A1
(en)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
|
CA3225636A1
(en)
|
2021-07-02 |
2023-01-05 |
Merck Patent Gmbh |
Anti-protac antibodies and complexes
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
WO2023104134A1
(en)
*
|
2021-12-09 |
2023-06-15 |
Genequantum Healthcare (Suzhou) Co., Ltd. |
Antibody-cytokine fusion proteins and applications thereof
|
|
US20260055119A9
(en)
*
|
2021-12-30 |
2026-02-26 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Tricyclic compound, method for preparing same, and use thereof
|
|
AU2023347072A1
(en)
*
|
2022-09-20 |
2025-01-02 |
Currus Biologics Pty Ltd |
Bispecific polypeptides and uses thereof
|
|
WO2024138128A2
(en)
*
|
2022-12-23 |
2024-06-27 |
Genentech, Inc. |
Cereblon degrader conjugates, and uses thereof
|
|
CN121240880A
(zh)
|
2022-12-27 |
2025-12-30 |
默克专利股份有限公司 |
Vhh抗protac抗体和复合物
|
|
CN121013863A
(zh)
*
|
2023-03-31 |
2025-11-25 |
艾菲赛尔治疗株式会社 |
Tnfr2结合多肽及使用方法
|
|
FR3147278A1
(fr)
*
|
2023-03-31 |
2024-10-04 |
Avacta Life Sciences Limited |
Polypeptides de liaison au tnfr2 et procedes d'utilisation
|
|
FR3147292A1
(fr)
*
|
2023-03-31 |
2024-10-04 |
Affyxell Therapeutics Co., Ltd. |
Cellules genetiquement modifiees dans lesquelles un acide nucleique codant pour des variantes de la proteine stefine a se liant specifiquement au tnfr2 ou une proteine de fusion comprenant celle-ci a ete introduite, et leurs utilisations
|
|
EP4713023A2
(en)
*
|
2023-05-18 |
2026-03-25 |
Firefly Bio, Inc. |
Isoindolinone-glutarimide antibody conjugates, and uses thereof
|
|
WO2024243545A1
(en)
*
|
2023-05-24 |
2024-11-28 |
President And Fellows Of Harvard College |
Compositions targeting endothelial cells and uses thereof
|
|
AR133955A1
(es)
|
2023-09-26 |
2025-11-19 |
Profoundbio Us Co |
Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
|
|
WO2025149661A1
(en)
|
2024-01-10 |
2025-07-17 |
Genmab A/S |
Slitrk6 binding agents, conjugates thereof and methods of using the same
|
|
EP4595981A1
(en)
*
|
2024-02-01 |
2025-08-06 |
Jack Elands |
Antibody-drug conjugates comprising an anti-integrin v 6 binding antibody
|
|
WO2025163120A1
(en)
*
|
2024-02-01 |
2025-08-07 |
Adcytherix Sas |
ANTIBODY-DRUG CONJUGATES COMPRISING AN ANTI-INTEGRIN ΑVβ6 BINDING ANTIBODY
|
|
US20250381289A1
(en)
|
2024-02-29 |
2025-12-18 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
WO2025216667A1
(en)
*
|
2024-04-12 |
2025-10-16 |
Joint Stock Company «Biocad» |
Monoclonal antibody that specifically binds to bdca-2
|